FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Top Story

FDA questions Cell Therapeutics' pixantrone

Ahead of Wednesday's advisory committee meeting, FDA staffers have raised questions about Cell Therapeutics' lymphoma drug pixantrone. The developer is hoping to market the therapy, also known as Pixuvri, as a treatment for patients with non-Hodgkin's lymphoma that hasn't responded to other treatments. Report

Special Report

Top 10 biopharma deals of 2009

If there was a hot trend for 2009 biopharma buyouts, it was the mega-merger. Three of the industry's biggest players--Wyeth, Genentech and Schering-Plough--were swept off the map in the first quarter of 2009, as Pfizer, Roche and Merck absorbed them into the fold. The rest of 2009's top deals were considerably smaller. Click here to begin the report and see the full list of the top 10 deals in biotech and pharma. Article

Special Report

FDA approvals of 2009

New DrugsWelcome to our look back at the new drug approvals of 2009. Last year the FDA gave the green light to 26 new therapies, slightly beating the 2008 total of 25. Of those, seven were newly-approved biologics, leading analysts to wonder whether 2009 was the year the biotech industry finally came into its own. The biggest NME winner was Novartis, which boasted four new approvals. The company was followed by Johnson & Johnson's Centocor Ortho Biotech and GlaxoSmithKline, with two approvals apiece. Slideshow ⇒

Profile

Emerging Drug Developer: Reata Pharmaceuticals

For a biotech with solid venture backing, some 50 employees and a significant licensing deal under its belt after reeling in convincing mid-stage data on a promising program for chronic kidney disease, Reata Pharmaceuticals made it through the last year with precious little media coverage. Profile